Pfizer Renewed as HKAPI Full Member
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) is pleased to announce that Pfizer has renewed as full member of the Association.
The President of the Association, Mr Raj Bhatti, said, “It strengthens the alignment of the industry stance that we are dedicated to bringing value to patients and the society, as well as safeguarding the industry’s ethics by implementing the Code of Practice.”
As one of the world’s premier innovative biopharmaceutical companies, Pfizer is committed to collaborating with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Maintaining the highest professional and ethical standards according to local and international laws, regulations and industry code requirements, is of utmost importance to the company.
In Hong Kong, Pfizer withdrew its HKAPI membership due to the challenges following the implementation of the sampling code policy by HKAPI in 2017. The challenges have since been resolved and Pfizer has renewed the full membership HKAPI to contribute to the continuous efforts of HKAPI to achieve its mission to drive expedient access to innovative healthcare solutions to benefit the people in Hong Kong and Macau with high ethical standards.
